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a  b  s  t  r  a  c  t
Background: This project compared HER-2/neu gene status in breast cancers, as demon-
strated by FISH (ﬂuorescent in situ hybridization) and CISH (chromogenic in situ
hybridization) and using a tissue microarray (TMA). The study also aimed to show whether
the  TMA technique could be used in clinical diagnostics, rather than remain a scientiﬁc tool.
Materials and methods: A TMA was constructed using 121 breast cancer specimens, 6 cores
from  each specimen. Demonstration and assessment of HER-2/neu gene status was by FISH
(Vysis  Path) and CISH (DAKO Duo CISH).
Results: The 121 breast cancer specimens were divided into 3 groups by HER-2 status, as
determined by immunohistochemistry. In the HER-2 negative group no ampliﬁcation was
observed in 36 out of 40 cases. 3 cases showed ampliﬁcation by both methods and one by
CISH alone. The equivocal HER-2 group showed no ampliﬁcation in 30 out of 41 cases and
ampliﬁcation in 9 cases. One case was FISH negative CISH positive and one was discarded. In
the  HER-2 positive group, ampliﬁcation was conﬁrmed in 37 of the 40 cases by both methods.
3  cases were unsuitable for assessment.
Conclusions: This study indicated that CISH is a sensitive alternative to FISH in detecting HER2
gene  ampliﬁcation and may replace FISH in HER2 testing. Good agreement was observedbetween methods (98.5% – 119 out of 121 cases).
Furthermore, as only 4 out of 121 cases were unsuitable for assessment (no signal or
missing TMA cores) – it may be feasible to use TMA in diagnostics.
©  2012 Greater Poland Cancer Centre, Poland. Published by Elsevier Urban & Partner Sp.1.  Background
One of the most important prognostic and predictive markers
in breast cancer is Human Epidermal Growth Factor Recep-
tor 2 (HER2), whose overexpression is associated with an
aggressive disease course. In many  Polish oncology centres,
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including the Greater Poland Cancer Centre in Poznan, HER2
status testing has been included in a routine diagnostic pro-
cedure applied to all new cases of breast cancer since 2001.9
The assessment is carried out according to an algorithmoland Cancer Centre, 15 Garbary Str., 61-866 Poznan´, Poland.
(Fig. 1). A routinely obtained result is veriﬁed, using the in situ
hybridization method, only in the event when the result is
borderline positive (15–30% of all cases),4 that is the result
hed by Elsevier Urban & Partner Sp. z.o.o. All rights reserved.




































sFig. 1 – The algorithm for the determ
f immunohistochemical HER2 assessment is graded 2+.
mongst patients with metastases to the lymph nodes, over-
xpression of HER2 is associated with a median survival period
f 3 years, while a 6–7 year survival period is an average
or patients without overexpression of HER2 in their cancer
ells.7,10,18
The value of HER2, both as a prognostic and as a predic-
ive factor, requires practical, repeatable, reliable and easily
ccessible assessment methods. In practice, methods for the
ssessment of HER2 status include immunohistochemistry
IHC) and in situ hybridization (ﬂuorescent – FISH and chro-
ogenic – CISH). Their value arises from the possibility of
ssessing the parameter of interest within preserved can-
er specimens (IHC) or within the nuclei of cancer cells
FISH, CISH) by means of an optical microscope (or a ﬂuores-
ence microscope in the case of the FISH method). Besides,
hese methods allow a simple testing of archival neoplas-
ic tissues stored in parafﬁn blocks. HER2 testing should be
erformed routinely in the case of patients with a diagnosis
f invasive breast cancer. Some controversy exists, however,
s to the best method for the determination of HER2 sta-
us. This concerns not only the choice of test, but also the
ptimal method for the application of that test to every
ase.11,16–18
In spite of efforts on the part of the international pathol-
gy community aimed at improving the status of HER2
esting in routine practice,6 inadequacies in immunohisto-
hemical and in situ hybridization tests remain a serious
roblem.16,17
For the purpose of saving both time and money, it seems
easonable to test as many  samples as possible on a sin-
le slide. The introduction of the tissue microarray (TMA)
echnique in 1986, with further subsequent improvements,
elped achieve this goal. This approach allows the assess-
ent of many  sections at a time by putting tens of tissue
ores into one parafﬁn block (up to 200 per block) and simulta-
eously reduces the amount of reagent required to test each
pecimen.1–3,13ion of HER2 status in breast cancers.
2. Aim
The aim of this study was to conﬁrm that:
1. The CISH method is concordant with the currently most
widely used FISH method, for the assessment of HER2/neu
status in breast cancer cells.
2. The TMA technique is a reliable and inexpensive approach
to the simultaneous assessment of HER2/neu status in
breast cancer samples taken from many  different patients.
3.  Materials  and  methods
The study group comprised of 121 women diagnosed in the
Greater Poland Cancer Centre in 2009, aged between 34 and 87
years, with a clinical diagnosis of invasive breast cancer.
Cases were excluded from the study if the originally diag-
nosed material had been obtained by ﬁne needle aspiration
biopsy or if the ﬁxation of the tissue had been insufﬁcient.
On the basis of a histopathological assessment of immuno-
histochemically stained slides (stained for overexpression of
the HER2 receptor), the group of 121 breast cancer cases was
subdivided into 3 groups (by IHC):
1) negative (IHC based HER2 receptor status: score 0/1)
2) equivocal (IHC based HER2 receptor status: score 2)
3) positive (IHC based HER2 receptor status: score 3)
Subsequently, on the basis of a histopathological assess-
ment of traditionally stained haematoxylin and eosin (H&E)
stained slides, areas of tissue containing cancerous cells were
selected. These areas deﬁned source material for the collec-
tion of tissue cores to be used in the construction of tissue
microarray (TMA) blocks.
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Fig. 2 – Tissue cores stained by haematoxylin and eosin
(magniﬁcation ×20).3.1.  Construction  of  the  tissue  microarray  (TMA)
From each of the selected parafﬁn blocks tissue cores were
sourced, as described above, and collected by means of
suitable needles (Beecher Instruments). These cores were
transferred to a special multi-tissue TMA  block. Six such cores,
of 0.6 mm in diameter, were selected from each specimen
for the purpose of reducing the risk of data loss through
destruction of cores during subsequent sectioning and stain-
ing procedures. The TMA  blocks were cut at a thickness of
4 m,  and the sections were mounted onto “Superfrost Plus”
microscope slides (Thermo Scientiﬁc). In total, 6 TMA  blocks
were prepared, each containing 6 tissue cores (thus ensuring
the presence of representative material) from each of the 20
cases of breast cancer.
The slides with sections from the TMA  blocks were deparaf-
ﬁnized and stained according to a traditional H&E method
(Fig. 2) and by immunohistochemistry (Fig. 3) for the purpose
of conﬁrming the presence of cancer tissue in each core of the
TMA. Identical TMA  sections were then stained according to
appropriate FISH and CISH (duo-CISH) procedures.
Fig. 3 – Tissue cores stained by immunohistochemistry
(magniﬁcation ×20).diotherapy 1 7 ( 2 0 1 2 ) 44–49
3.2. FISH  staining  according  to  the  “Path  Vysion”
method  for  the  “Vysis”  HER-2/neu  probe  kit
Slides bearing TMA sections were deparafﬁnized and rehy-
drated prior to incubation in “Pre-Treatment Solution” at 80 ◦C
in a water bath for 30 min. Subsequently, the samples were
subjected to protease enzymatic digestion in a water bath at
37 ◦C for 15 min. In later phases of the procedure we  carried
out denaturation and hybridization with a molecular probe in
a hybridizer (denaturation at 72 ◦C for 5 min. and hybridiza-
tion at 37 ◦C for 14–20 h). The following day the samples were
rinsed in post-hybridization buffer to remove unbound probe
(72 ◦C for 5 min. in a water bath). The complex was visu-
alised using DAPI ﬂuorescent complex. The specimens were
mounted under cover-slips and examined using a ﬂuores-
cence microscope.
3.3.  Assessment  system  for  ﬂuorescent  in  situ
hybridization
The FISH tests were carried out using proprietary probes from
PathVysionTM (Abbott/Vysis: LSI® HER2 Spectrum OrangeTM
and CEP 17 Spectrum – GreenTM).
Analysis of signals was performed by 2 independent
observers using a ﬂuorescence microscope (magniﬁcation
×1000). Hybridization signals were counted in 20 cell nuclei
from each core. A negative result was recorded if the FISH
coefﬁcient was <1.8 or when the copy number of the Her-2/neu
gene was <4.0. A positive result for ampliﬁcation of the Her-
2/neu gene was recorded if the FISH coefﬁcient was >2.2 or the
gene copy number was >6.0. In the event when the FISH coefﬁ-
cient was found to be between 1.8 and 2.2, or the copy number
was found to be between 4.0 and 6.0, cases were deemed to be
equivocal.
3.4.  CISH  staining  according  to  the  “Dako  Duo  CISH”
method  for  the  “HER2  CISH  pharmDxTM”  probe  kit
Slides bearing TMA sections were deparafﬁnized and rehy-
drated prior to incubation in “Pre-Treatment Solution” at
95–99 ◦C in a water bath for 10 min. Subsequently, the samples
were subjected to enzymatic digestion in pepsin at 37 ◦C in a
hybridizer for 6 min. This was followed by denaturation and
hybridization with a molecular probe in a hybridizer (denatu-
ration at 82 ◦C for 5 min  and hybridization at 45 ◦C for 14–20 h).
The following day, unbound probe was rinsed away using
Stringent Washing buffer (65 ◦C for 10 min) in a water bath. In
later phases of the procedure, endogenous peroxidase activ-
ity was blocked, followed by incubation with CISH antibody
mixture. For visualisation, the Red and Blue Chromogen com-
plexes were applied. Cell nuclei were stained in haematoxylin.
The slides were sealed using a sealing mountant (Tissue-
mount) and coverslipped prior to assessment using an optical
microscope.
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Fig. 4 – FISH showing no ampliﬁcation of the HER2 gene in
invasive breast cancer. The HER2 gene is seen as a red
signal while the centromeres of chromosome 17 are seen
as green signals. This test is negative for ampliﬁcation of
difﬁculties in the interpretation of results – the possibility of
having several copies of a gene visible in one place when cell
nuclei are aligned in stacks in thick sections.10 Despite those
shortcomings, the CISH method still has many  advantages. In
Fig. 5 – FISH showing ampliﬁcation of the HER2 gene in
invasive breast cancer. Gene HER2 is seen here as a redNo result 4 0
Total 121 121
.5.  Assessment  system  for  chromogenic  in  situ
ybridization
ISH tests were performed using proprietary DNA probes from
ako (HER2 CISH pharmDxTM. HER2 Spectrum Red and CEP 17
pectrum – Blue).
An analysis of the signals was carried out by 2 independent
bservers using an optical microscope (magniﬁcation ×1000).
ybridization signals were counted for 20 cell nuclei in each
ore. A result for ampliﬁcation of the Her-2/neu gene was
ounted as negative if the FISH coefﬁcient was <1.8 or the copy
umber of the Her-2/neu gene was <4.0. A positive result for
mpliﬁcation of the Her-2/neu gene was recorded if the FISH
oefﬁcient was >2.2 or if the Her-2/neu gene copy number was
6. Cases where the FISH coefﬁcient was between 1.8 and 2.2
r where the Her-2/neu gene copy number was between 4.0
nd 6.0 were deemed to be equivocal.
.  Results
21 cases of breast cancer from patients diagnosed in the
reater Poland Cancer Centre in Poznan in 2009 were ana-
ysed. These cases were divided into 3 groups (according to
heir HER-2 status, as determined by immunohistochemistry
IHC)). Six tissue microarrays were constructed using 6 tissue
ores from each patient. The results of all FISH and CISH tests
re shown in Table 1.
From among the 121 cases analysed, the FISH method
howed no ampliﬁcation of the HER2 gene in 68 cases (Fig. 4)
nd ampliﬁcation of the gene in 49 cases (Fig. 5). Due to tech-
ical issues, 4 cases could not be analysed using the FISH
ethod (either there were no signals seen during microscopic
xaminations or insufﬁcient TMA  spots were available for
hat patient). Using the CISH method, 66 cases showed no
mpliﬁcation (Fig. 6), while the remaining 55 cases showed
mpliﬁcation of the HER-2 gene (Fig. 7). In the 4 cases where
ISH could not be used, the CISH procedure showed ampliﬁca-
ion. CISH also showed ampliﬁcation in 2 cases which FISH had
hown to be negative. The results broken down into the tested
roups (HER2 negative, equivocal and positive) are shown in
he Tables 2–4.
.  Discussion
uring this project it was noted that the CISH technique is
oth a sensitive and speciﬁc method for the detection of HER- and could be used in the same role as FISH in the HER2
esting algorithm. The observed level of agreement between
he two methods was 98.5% (119 cases out of 121). The in situthe HER2 gene as the ratio HER2/CEP17 is less than 1.8.
hybridization method was compared with immunohisto-
chemistry in other studies, where the level of agreement
ranged from 75% to 99%.2,5,8,10,14,15,19,20 For example, compar-
ing our results with those presented by Hannah et al.,10 the
level of agreement between FISH and CISH in the three groups
stratiﬁed according to HER2-IMH status was slightly lower in
our study. The explanation for this difference is probably the
number of patients in the group studied by Hannah, which
was more  than a half larger than our group. In general, the
discrepancies between the methods (FISH negative, CISH pos-
itive) could be explained by the occurrence of chromosome
17 polysomy or incorrect counting of unspeciﬁc deposits in
the cell nuclei. Hannah et al. also described the most frequentsignal while the centromeres of chromosome 17 are green.
A high level of ampliﬁcation of the HER2 gene is evident
from the HER2/CEP17 ratio which is higher than 1.8.
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Table 2 – Correlation between FISH and CISH in the 40 cases of breast cancer of the HER-2 negative group (as assessed by
immunohistochemistry).
CISH− CISH+ Unsuitable for
CISH assessment
FISH− 36 90% 1 2.5% 0
FISH+ 0 0 3 7.5% 0
Unsuitable for FISH assessment 0 0 0 0
Table 3 – Correlation between FISH and CISH in the 41 breast cancer cases of the HER-2 equivocal group (as assessed by
immunohistochemistry).
CISH− CISH+ Unsuitable for
CISH assessment
FISH− 30 73% 1 2.5% 0
FISH+ 0 9 22% 0
Unsuitable for FISH assessment 0 1 2.5% 0
Table 4 – Correlation between FISH and CISH in the 40 cases of breast cancer of the HER-2 positive group (as assessed by
immunohistochemistry).
CISH− CISH+ Unsuitable for
CISH assessmentFISH− 0 
FISH+ 0 
Unsuitable for FISH assessment 0 
comparison to FISH, the CISH method does not require access
to expensive equipment for analysis of results. Interpretation
of the results is done using an ordinary optical microscope and
does not require work in the dark (as is the case when using
a ﬂuorescence microscope for the FISH method). The CISH
method also offers the possibility to make a simultaneous ver-
iﬁcation of the structure of tissues as well as to archive slides
for longer periods than is possible with the FISH method.10,15,19
The question of whether or not tissue cores can be repre-
sentative of whole tumours is frequently raised in regard to
the TMA  technique. The majority of tumours are of hetero-
geneous nature and a small sample of tissue will not always
display the same biological characteristics as a whole tumour.
Fig. 6 – CISH showing no ampliﬁcation of the HER2 gene in
invasive breast cancer. The HER2 gene is seen as a red
signal while the centromeres of chromosome 17 are seen
as dark-blue/black signals. This test is negative for
ampliﬁcation of the HER2 gene as the ratio HER2/CEP17 is
less than 1.8.0 0
37 92.5% 0
3 7.5% 0
For this reason, the TMA technique is also frequently ques-
tioned as a useful diagnostic tool and is usually used only
in scientiﬁc studies. In order to increase the credibility of the
TMA technique while reducing the likelihood of error associ-
ated with the difﬁculty of obtaining a representative sample,
many  authors use several cores from the same donor tissues.
There are several papers discussing the issue of the num-
ber of cores that are needed to produce comparable results
to those obtained from whole sections. Some of the authors,
like Jourdan et al.,12 found that only a few (up to four) cores
are required to achieve a 100% agreement. Others, like Camp
et al.,3 found, however, that even when as many  as 10 tissue
cores are taken from a tumour, some disagreement may be
Fig. 7 – CISH showing ampliﬁcation of the HER2 gene in
invasive breast cancer. Gene HER2 is seen here as a red
signal while the centromeres of chromosome 17 are
dark-blue/black. A high level of ampliﬁcation of the HER2






















































1reports of practical oncology an
oted in the results. In our opinion, it should be noted that the
xperience of the person responsible for collection of material
rom the source samples is of signiﬁcance. In order to ensure
hat the material used in this study would be representative,
 cores of tissue were collected from each case.
In our study the agreement between the HER2 recep-
or using FISH on microarray material and on full sections
mounted to 95% and was slightly better than that achieved in
 study by O’Grady et al. 14 They showed the advantages of the
issue microarray technique, such as having various primary
umours in a single parafﬁn block which allows a simulta-
eous analysis of a great many  cases with the use of very
ew slides. These slides also have the advantage of ensuring
hat all the tissue samples are treated using exactly the same
onditions for staining or marker demonstration while using
igniﬁcantly less tissue for the test.
In the results of this study, only 4 out of 121 cases tested
y the TMA  method could not be assessed (owing to a lack
f signal or TMA  cores) – which suggests that it is possible to
pply tissue microarrays to clinical diagnostics. At the same
ime, the use of TMA  allows the reduction of costs associated
ith testing for the ampliﬁcation of the HER-2/neu gene using
n situ hybridization techniques. This in turn could allow the
ntroduction of the TMA  technique to routine clinical diag-
ostics in all cases of breast cancer, not only borderline cases
those where immunohistochemistry for the HER2 receptor
as scored as 2+).
. Conclusions
n conclusion, the results of this study show that CISH may be
n alternative to the FISH method in the assessment of HER2
ene ampliﬁcation for all patients with invasive breast can-
er, using equipment widely available in diagnostic pathology
aboratories. We  also conﬁrmed the suitability of the tissue
icroarray technique for a simultaneous assessment of HER2
ene ampliﬁcation status in tumours arising from tens of
ifferent patients, while maintaining a representative tissue
ample in each case, with good reproducibility and credible
esults. It would not be unreasonable to assume that further
mprovements to the techniques described in this study may
oon lead to a reduction in costs and improved turnaround
ime in the diagnostic process.
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